February 2025 Update
Phrenix Therapeutics is pleased to announce the successful close of our seed funding round, backed by leading venture capital firms Curie.Bio and Brandon Capital.
This investment accelerates our pipeline towards the clinic, advancing highly targeted therapeutics for cognitive, psychiatric, and neurological conditions and bringing us closer to transforming the lives of individuals, families, and communities.
We’re excited to start the next phase of our company’s journey and look forward to working with our new partners to drive meaningful advances in neuroscience drug discovery.
Read more here.

Our Pipeline

Enhanced drug discovery
Using structure-guided design and disease-relevant analytical pharmacology, we are developing a pipeline of G protein-coupled receptor (GPCR) targeted therapeutics for psychiatric and neurological disorders.
Reimagining translation in psychiatry
We use rodent touchscreen-based technologies to evaluate targets and assess pro-cognitive compound efficacy. Unlike much psychiatry R&D in the past 50 years, our testing reflects clinical outcomes.
